Differential inhibitory effects of cyanovirin-N, griffithsin, and scytovirin on entry mediated by envelopes of gammaretroviruses and deltaretroviruses

Journal of Virology

Volumn 88, Issue 4, 2014, Pages 2327-2332

  Jensen, Stig M R ^a,c   Ruscetti, Francis W ^a   Rein, Alan ^a   Bertolette, Daniel C ^a   Saucedo, Carrie J ^a   O'Keefe, Barry R ^b   Jones, Kathryn S ^b,d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d Howard Community College   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEINS; CARRIER PROTEINS; GAMMARETROVIRUS; GLYCOSYLATION; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; LECTINS; PLANT LECTINS; VIRAL ENVELOPE PROTEINS; VIRUS INTERNALIZATION;

EID: 84893438784     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02553-13     Document Type: Article

References (48)

1. Weis WI, Taylor ME, Drickamer K. 1998. The C-type lectin superfamily in the immune system. Immunol. Rev. 163:19-34. http://dx.doi.org/10.1111/j.1600-065X.1998.tb01185.x.
2. Balzarini J, Neyts J, Schols D, Hosoya M, Van Damme E, Peumans W, De Clercq E. 1992. The mannose-specific plant lectins from Cymbidium hybrid and Epipactis helleborine and the (N-acetylglucosamine)n-specific plant lectin from Urtica dioica are potent and selective inhibitors of human immunodeficiency virus and cytomegalovirus replication in vitro. Antiviral Res. 18: 191-207. http://dx.doi.org/10.1016/0166-3542(92)90038-7.
3. Balzarini J, Schols D, Neyts J, Van Damme E, Peumans W, De Clercq E. 1991. Alpha-(1-3)-and alpha-(1-6)-D-mannose-specific plant lectins are markedly inhibitory to human immunodeficiency virus and cytomegalovirus infections in vitro. Antimicrob. Agents Chemother. 35:410-416. http://dx.doi.org/10.1128/AAC.35.3.410.
4. Boyd MR, Gustafson KR, McMahon JB, Shoemaker RH, O'Keefe BR, Mori T, Gulakowski RJ, Wu L, Rivera MI, Laurencot CM, Currens MJ, Cardellina JH, II, Buckheit RW, Jr, Nara PL, Pannell LK, Sowder RC, II, Henderson LE. 1997. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob. Agents Chemother. 41:1521-1530.
5. Hansen JE, Nielsen C, Vestergaard BF. 1991. Inhibition of human immunodeficiency virus 1 (HIV-1) and herpes simplex virus 1 (HSV-1) infectivity with a broad range of lectins. Scand. J. Infect. Dis. 23:425-430. http://dx.doi.org/10.3109/00365549109075090.
6. Mori T, O'Keefe BR, Sowder RC, II, Bringans S, Gardella R, Berg S, Cochran P, Turpin JA, Buckheit RW, Jr, McMahon JB, Boyd MR. 2005. Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. J. Biol. Chem. 280:9345-9353. http://dx.doi.org/10.1074/jbc.M411122200.
7. Mori T, Shoemaker RH, Gulakowski RJ, Krepps BL, McMahon JB, Gustafson KR, Pannell LK, Boyd MR. 1997. Analysis of sequence requirements for biological activity of cyanovirin-N, a potent HIV (human immunodeficiency virus)-inactivating protein. Biochem. Biophys. Res. Commun. 238:218-222. http://dx.doi.org/10.1006/bbrc.1997.7202.
8. O'Keefe BR, Smee DF, Turpin JA, Saucedo CJ, Gustafson KR, Mori T, Blakeslee D, Buckheit R, Boyd MR. 2003. Potent anti-influenza activity of cyanovirin-N and interactions with viral hemagglutinin. Antimicrob. Agents Chemother. 47:2518-2525. http://dx.doi.org/10.1128/AAC.47.8.2518-2525.2003.
9. Barrientos LG, O'Keefe BR, Bray M, Sanchez A, Gronenborn AM, Boyd MR. 2003. Cyanovirin-N binds to the viral surface glycoprotein, GP1,2 and inhibits infectivity of Ebola virus. Antiviral Res. 58:47-56. http://dx.doi.org/10.1016/S0166-3542(02)00183-3.
10. Barrientos LG, Lasala F, Otero JR, Sanchez A, Delgado R. 2004. In vitro evaluation of cyanovirin-N antiviral activity, by use of lentiviral vectors pseudotyped with filovirus envelope glycoproteins. J. Infect. Dis. 189: 1440-1443. http://dx.doi.org/10.1086/382658.
11. Keyaerts E, Vijgen L, Pannecouque C, Van Damme E, Peumans W, Egberink H, Balzarini J, Van Ranst M. 2007. Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle. Antiviral Res. 75:179-187. http://dx.doi.org/10.1016/j.antiviral.2007.03.003.
12. Helle F, Wychowski C, Vu-Dac N, Gustafson KR, Voisset C, Dubuisson J. 2006. Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans. J. Biol. Chem. 281:25177-25183. http://dx.doi.org/10.1074/jbc.M602431200.
13. Dey B, Lerner DL, Lusso P, Boyd MR, Elder JH, Berger EA. 2000. Multiple antiviral activities of cyanovirin-N: blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses. J. Virol. 74:4562-4569. http://dx.doi.org/10.1128/JVI.74.10.4562-4569.2000.
14. Bokesch HR, O'Keefe BR, McKee TC, Pannell LK, Patterson GM, Gardella RS, Sowder RC, II, Turpin J, Watson K, Buckheit RW, Jr, Boyd MR. 2003. A potent novel anti-HIV protein from the cultured cyanobacterium Scytonema varium. Biochem. J. 42:2578-2584. http://dx.doi.org/10.1021/bi0205698.
15. Alexandre KB, Gray ES, Lambson BE, Moore PL, Choge IA, Mlisana K, Karim SS, McMahon J, O'Keefe B, Chikwamba R, Morris L. 2010. Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin. Virology 402:187-196. http://dx.doi.org/10.1016/j.virol.2010.03.021.
16. Giomarelli B, Schumacher KM, Taylor TE, Sowder RC, II, Hartley JL, McMahon JB, Mori T. 2006. Recombinant production of anti-HIV protein, griffithsin, by auto-induction in a fermentor culture. Protein Expr. Purif. 47:194-202. http://dx.doi.org/10.1016/j.pep.2005.10.014.
17. O'Keefe BR, Vojdani F, Buffa V, Shattock RJ, Montefiori DC, Bakke J, Mirsalis J, d'Andrea AL, Hume SD, Bratcher B, Saucedo CJ, McMahon JB, Pogue GP, Palmer KE. 2009. Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. Proc. Natl. Acad. Sci. U.S.A. 106:6099-6104. http://dx.doi.org/10.1073/pnas.0901506106.
18. Xiong C, O'Keefe BR, Byrd RA, McMahon JB. 2006. Potent anti-HIV activity of scytovirin domain 1 peptide. Peptides 27:1668-1675. http://dx.doi.org/10.1016/j.peptides.2006.03.018.
19. Ziolkowska NE, O'Keefe BR, Mori T, Zhu C, Giomarelli B, Vojdani F, Palmer KE, McMahon JB, Wlodawer A. 2006. Domain-swapped structure of the potent antiviral protein griffithsin and its mode of carbohydrate binding. Structure 14:1127-1135. http://dx.doi.org/10.1016/j.str.2006.05.017.
20. Lagenaur LA, Sanders-Beer BE, Brichacek B, Pal R, Liu X, Liu Y, Yu R, Venzon D, Lee PP, Hamer DH. 2011. Prevention of vaginal SHIV transmission in macaques by a live recombinant Lactobacillus. Mucosal Immunol. 4:648-657. http://dx.doi.org/10.1038/mi.2011.30.
21. Tsai CC, Emau P, Jiang Y, Agy MB, Shattock RJ, Schmidt A, Morton WR, Gustafson KR, Boyd MR. 2004. Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Res. Hum. Retroviruses 20:11-18. http://dx.doi.org/10.1089/088922204322749459.
22. Tsai CC, Emau P, Jiang Y, Tian B, Morton WR, Gustafson KR, Boyd MR. 2003. Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89.6P in macaques. AIDS Res. Hum. Retroviruses 19: 535-541. http://dx.doi.org/10.1089/088922203322230897.
23. Jones KS, Akel S, Petrow-Sadowski C, Huang Y, Bertolette DC, Ruscetti FW. 2005. Induction of human T cell leukemia virus type I receptors on quiescent naive T lymphocytes by TGF-beta. J. Immunol. 174:4262-4270.
24. Herrler G, Compans RW. 1983. Posttranslational modification and intracellular transport of mumps virus glycoproteins. J. Virol. 47:354-362.
25. Hunt LA, Etchison JR, Summers DF. 1978. Oligosaccharide chains are trimmed during synthesis of the envelope glycoprotein of vesicular stomatitis virus. Proc. Natl. Acad. Sci. U.S.A. 75:754-758. http://dx.doi.org/10.1073/pnas.75.2.754.
26. Hunt LA, Summers DF. 1976. Glycosylation of vesicular stomatitis virus glycoprotein in virus-infected HeLa cells. J. Virol. 20:646-657.
27. Hardy WD, Jr, Old LJ, Hess PW, Essex M, Cotter S. 1973. Horizontal transmission of feline leukaemia virus. Nature 244:266-269. http://dx.doi.org/10.1038/244266a0.
28. Jarrett O, Russell PH. 1978. Differential growth and transmission in cats of feline leukaemia viruses of subgroups A and B. Int. J. Cancer 21:466-472. http://dx.doi.org/10.1002/ijc.2910210411.
29. Esser MT, Mori T, Mondor I, Sattentau QJ, Dey B, Berger EA, Boyd MR, Lifson JD. 1999. Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120. J. Virol. 73:4360-4371.
30. Gillette WK, Esposito D, Taylor TE, Hopkins RF, Bagni RK, Hartley JL. 2011. Purify First: rapid expression and purification of proteins from XMRV. Protein Expr. Purif. 76:238-247. http://dx.doi.org/10.1016/j.pep.2010.12.003.
31. Bewley CA. 2001. Solution structure of a cyanovirin-N:Man alpha 1-2Man alpha complex: structural basis for high-affinity carbohydratemediated binding to gp120. Structure 9:931-940. http://dx.doi.org/10.1016/S0969-2126(01)00653-0.
32. Oliveira NM, Farrell KB, Eiden MV. 2006. In vitro characterization of a koala retrovirus. J. Virol. 80:3104-3107. http://dx.doi.org/10.1128/JVI.80.6.3104-3107.2006.
33. Oliveira NM, Satija H, Kouwenhoven IA, Eiden MV. 2007. Changes in viral protein function that accompany retroviral endogenization. Proc. Natl. Acad. Sci. U.S.A. 104:17506-17511. http://dx.doi.org/10.1073/pnas.0704313104.
34. Battini JL, Danos O, Heard JM. 1995. Receptor-binding domain of murine leukemia virus envelope glycoproteins. J. Virol. 69:713-719.
35. Battini JL, Heard JM, Danos O. 1992. Receptor choice determinants in the envelope glycoproteins of amphotropic, xenotropic, and polytropic murine leukemia viruses. J. Virol. 66:1468-1475.
36. Bae Y, Kingsman SM, Kingsman AJ. 1997. Functional dissection of the Moloney murine leukemia virus envelope protein gp70. J. Virol. 71:2092-2099.
37. Lavillette D, Ruggieri A, Russell SJ, Cosset FL. 2000. Activation of a cell entry pathway common to type C mammalian retroviruses by soluble envelope fragments. J. Virol. 74:295-304. http://dx.doi.org/10.1128/JVI.74.1.295-304.2000.
38. Zavorotinskaya T, Albritton LM. 1999. Suppression of a fusion defect by second site mutations in the ecotropic murine leukemia virus surface protein. J. Virol. 73:5034-5042.
39. Seiki M, Hattori S, Hirayama Y, Yoshida M. 1983. Human adult T-cell leukemia virus: complete nucleotide sequence of the provirus genome integrated in leukemia cell DNA. Proc. Natl. Acad. Sci. U.S.A. 80:3618-3622. http://dx.doi.org/10.1073/pnas.80.12.3618.
40. Cunningham MW, Brown MA, Shindle DB, Terrell SP, Hayes KA, Ferree BC, McBride RT, Blankenship EL, Jansen D, Citino SB, Roelke ME, Kiltie RA, Troyer JL, O'Brien SJ. 2008. Epizootiology and management of feline leukemia virus in the Florida puma. J. Wildl. Dis. 44:537-552. http://dx.doi.org/10.7589/0090-3558-44.3.537.
41. Thalwitzer S, Wachter B, Robert N, Wibbelt G, Muller T, Lonzer J, Meli ML, Bay G, Hofer H, Lutz H. 2010. Seroprevalences to viral pathogens in free-ranging and captive cheetahs (Acinonyx jubatus) on Namibian farmland. Clin. Vaccine Immunol. 17:232-238. http://dx.doi.org/10.1128/CVI.00345-09.
42. Geret CP, Cattori V, Meli ML, Riond B, Martinez F, Lopez G, Vargas A, Simon MA, Lopez-Bao JV, Hofmann-Lehmann R, Lutz H. 2011. Feline leukemia virus outbreak in the critically endangered Iberian lynx (Lynx pardinus): high-throughput sequencing of envelope variable region Aand experimental transmission. Arch. Virol. 156:839-854. http://dx.doi.org/10.1007/s00705-011-0925-z.
43. Willi B, Filoni C, Catao-Dias JL, Cattori V, Meli ML, Vargas A, Martinez F, Roelke ME, Ryser-Degiorgis MP, Leutenegger CM, Lutz H, Hofmann-Lehmann R. 2007. Worldwide occurrence of feline hemoplasma infections in wild felid species. J. Clin. Microbiol. 45:1159-1166. http://dx.doi.org/10.1128/JCM.02005-06.
44. Levy J, Crawford C, Hartmann K, Hofmann-Lehmann R, Little S, Sundahl E, Thayer V. 2008. 2008 American Association of Feline Practitioners' feline retrovirus management guidelines. J. Feline Med. Surg. 10: 300-316. http://dx.doi.org/10.1016/j.jfms.2008.03.002.
45. Huskens D, Vermeire K, Vandemeulebroucke E, Balzarini J, Schols D. 2008. Safety concerns for the potential use of cyanovirin-N as a microbicidal anti-HIV agent. Int. J. Biochem. Cell Biol. 40:2802-2814. http://dx.doi.org/10.1016/j.biocel.2008.05.023.
46. Buffa V, Stieh D, Mamhood N, Hu Q, Fletcher P, Shattock RJ. 2009. Cyanovirin-N potently inhibits human immunodeficiency virus type 1 infection in cellular and cervical explant models. J. Gen. Virol. 90:234-243. http://dx.doi.org/10.1099/vir.0.004358-0.
47. Logg CR, Baranick BT, Lemp NA, Kasahara N. 2007. Adaptive evolution of a tagged chimeric gammaretrovirus: identification of novel cis-acting elements that modulate splicing. J. Mol. Biol. 369:1214-1229. http://dx.doi.org/10.1016/j.jmb.2007.04.026.
48. Donahue PR, Hoover EA, Beltz GA, Riedel N, Hirsch VM, Overbaugh J, Mullins JI. 1988. Strong sequence conservation among horizontally transmissible, minimally pathogenic feline leukemia viruses. J. Virol. 62: 722-731.